Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Goldhardt

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Clinical ManifestationsSophia Holzhauser, Oliver Goldhardt, Patrick Sommer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 17, 2025
Elecsys CSF AD immunoassays: Sample stability for a new pre-analytical protocol for fresh CSFEkaterina Manuilova, Isabelle Schrurs, Sandra Rutz, et al.
Alzheimer'S Research & Therapy|April 27, 2022
Cerebrospinal fluid lactate levels along the Alzheimer's disease continuum and associations with blood-brain barrier integrity, age, cognition, and biomarkersPaul Theo Zebhauser, Achim Berthele, Oliver Goldhardt, et al.
Alzheimer'S Research & Therapy|April 27, 2022
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohortMichaela Amft, Marion Ortner, Udo Eichenlaub, et al.
Journal of Alzheimer'S Disease : JAD|July 12, 2021
Age-Dependency of Total Tau in the Cerebrospinal Fluid Is Corrected by Amyloid-β 1-40: A Correlational Study in Healthy AdultsPaul Theo Zebhauser, Achim Berthele, Marie-Sophie Franz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 21, 2015
Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive ImpairmentTimo Grimmer, Carolin Wutz, Panagiotis Alexopoulos, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 23, 2020
Variability of clinical syndromes and cerebral glucose metabolism in symptomatic frontotemporal lobar degeneration associated with progranulin mutationsAbigail Licata, Timo Grimmer, Juliane Winkelmann, et al.
Journal of Proteomics|April 24, 2018
Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approachIlijana Begcevic, Davor Brinc, Marshall Brown, et al.
Translational Neurodegeneration|August 31, 2019
Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PETOliver Goldhardt, Inanna Warnhoff, Igor Yakushev, et al.
Neuro-Degenerative Diseases|July 3, 2019
Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's DiseaseTimo Grimmer, Oliver Goldhardt, Igor Yakushev, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Clinical ManifestationsSophia Holzhauser, Oliver Goldhardt, Patrick Sommer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 17, 2025
Elecsys CSF AD immunoassays: Sample stability for a new pre-analytical protocol for fresh CSFEkaterina Manuilova, Isabelle Schrurs, Sandra Rutz, et al.
Alzheimer'S Research & Therapy|April 27, 2022
Cerebrospinal fluid lactate levels along the Alzheimer's disease continuum and associations with blood-brain barrier integrity, age, cognition, and biomarkersPaul Theo Zebhauser, Achim Berthele, Oliver Goldhardt, et al.
Alzheimer'S Research & Therapy|April 27, 2022
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohortMichaela Amft, Marion Ortner, Udo Eichenlaub, et al.
Journal of Alzheimer'S Disease : JAD|July 12, 2021
Age-Dependency of Total Tau in the Cerebrospinal Fluid Is Corrected by Amyloid-β 1-40: A Correlational Study in Healthy AdultsPaul Theo Zebhauser, Achim Berthele, Marie-Sophie Franz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 21, 2015
Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive ImpairmentTimo Grimmer, Carolin Wutz, Panagiotis Alexopoulos, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 23, 2020
Variability of clinical syndromes and cerebral glucose metabolism in symptomatic frontotemporal lobar degeneration associated with progranulin mutationsAbigail Licata, Timo Grimmer, Juliane Winkelmann, et al.
Journal of Proteomics|April 24, 2018
Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approachIlijana Begcevic, Davor Brinc, Marshall Brown, et al.
Translational Neurodegeneration|August 31, 2019
Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PETOliver Goldhardt, Inanna Warnhoff, Igor Yakushev, et al.
Neuro-Degenerative Diseases|July 3, 2019
Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's DiseaseTimo Grimmer, Oliver Goldhardt, Igor Yakushev, et al.
Pageof 4